Physician profile
Robert Finlaw
NPI 1093744310
$2,257.58
in general payments reported to CMS, 2019-2025
20 companies · $439 in 2025
The $439 reported for 2025 was more than what 76% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2020: $296 · 2021: $298 · 2022: $326 · 2023: $330 · 2024: $353 · 2025: $439.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,174.60 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $141.93 | 2019-2020 | |
| Pfizer INC. | $115.89 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.40 | 2019-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $104.27 | 2019-2025 | Tremfya, Stelara |
| Intercept Pharmaceuticals, INC. | $82.83 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.69 | 2019-2022 | |
| Daiichi Sankyo INC. | $70.49 | 2019-2022 | |
| Braintree Laboratories, INC. | $70.18 | 2019-2023 | Suflave |
| Gilead Sciences, INC. | $58.19 | 2024-2025 | |
| Celgene Corporation | $52.10 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $39.29 | 2021 | |
| Madrigal Pharmaceuticals | $35.45 | 2025 | Rezdiffra |
| Genzyme Corporation | $24.78 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $24.69 | 2023 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $19.59 | 2020 | |
| Ardelyx, INC. | $15.86 | 2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $15.51 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.74 | 2021 | |
| Vivus LLC | $14.10 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Finlaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.